Articles tagged with Breast Carcinoma
A comprehensive review of breast cancer risk models in women with a family history found that none are highly accurate at identifying which women will develop the disease. The BOADICEA model showed balanced performance, while others had significant limitations, emphasizing the need for continued improvement.
Researchers discover that kinases play a crucial role in moving cholesterol to activate a growth pathway in aggressive cancers. Without these enzymes, cancer cells are blocked from fueling tumor growth. The study highlights the importance of targeting lipid enzymes as a potential treatment strategy for cancers with TP53 mutations.
Dr. Dennis Slamon, a renowned breast cancer researcher, has been elected to the Association of American Physicians (AAP) for his pioneering work in HER2 gene discovery and targeted therapies. His research led to significant improvements in survival rates and established the principle of targeted cancer treatment.
A study by the CNIO group has identified a genetic signature in precancerous breast lesions that can predict which ones will evolve into invasive tumours. This discovery could help avoid over-treatment of women diagnosed with ductal carcinoma in situ, a common precancerous lesion.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
A new analysis shows elinzanetant effectively relieves moderate-to-severe vasomotor symptoms (VMS) associated with endocrine therapy, regardless of the type of hormone treatment. The drug reduces VMS frequency and severity by blocking a protein that triggers these symptoms.
A pilot study found that axillary radiotherapy may be as effective as surgery in killing cancer cells while reducing the risk of painful swelling. The trial compared radiotherapy to axillary lymph node dissection and found similar cancer outcomes, but lower rates of lymphoedema after radiotherapy.
Singapore's breast cancer incidence is rising, but mortality rates are falling, mirroring global trends. The country's strong healthcare system and high-screening participation have contributed to improved survival rates.
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
Researchers review the molecular mechanisms of mitophagy in breast cancer, highlighting its potential as a biomarker and therapeutic target. The study suggests that strategic modulation of mitophagy can enhance personalized treatment approaches for BC.
Researchers developed polygenic risk score models to predict breast cancer risk in women of African ancestry, improving accuracy and performance compared to existing models. The new tools could lead to earlier screening, tailored care, and increased survival rates for high-risk women.
A study published by the National Institutes for Quantum Science and Technology found that carbon-ion radiotherapy provided durable tumor control with minimal side effects while preserving breast appearance in carefully selected patients who were unable or unwilling to undergo surgery. The treatment resulted in excellent local control ...
Researchers found that Fusobacterium nucleatum accelerates tumor growth and increases cancer cell spread in animal models of human breast cancer, particularly in cells with BRCA1 gene mutations. The study reveals a connection between oral microbes and breast cancer risk and progression.
A large-scale international study has deciphered a mechanism enabling breast cancer to metastasize to the brain. Researchers identified a specific chromosomal alteration predicting high likelihood of brain metastases and found that the absence of functional p53 gene impairs brain environment adaptation.
Researchers have discovered a pathway that makes estrogen receptor-positive breast cancer tumors responsive to immunotherapy. By inhibiting the estrogen receptor, LCOR molecule activation is enabled, allowing tumor cells to become visible to the immune system.
Researchers studied MALAT1 levels in a woman with triple-negative breast cancer, finding high levels at diagnosis and decreased while receiving treatment. Notably, levels increased at a distant metastatic site, suggesting MALAT1's role in TNBC's spread. The study informs future treatments and potential clinical trials.
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
Researchers at OHSU develop a promising drug SU212 to treat intractable cases of triple-negative breast cancer. The molecule binds to and degrades the enzyme enolase 1, suppressing tumor growth and metastasis in humanized mouse models.
The study found that a nine-month programme of supervised exercise improved muscle mass and strength, particularly in the arms and legs, and physical performance in patients with breast cancer that had spread to other parts of the body. Muscle mass increased by an average of 0.79 kg after three months and 0.32 kg after six months compa...
Researchers at University of Miami Miller School of Medicine have developed a new combination therapy that shrinks tumors, reduces cancer stem cells and reprograms immune environment to combat hormone-resistant breast cancer. The triple therapy approach targets tumor-associated macrophages, which act like bodyguards for cancer cells.
A global survey of nearly 4,000 young women with advanced breast cancer found that nearly half have children under 18 and face significant hardship. The study also revealed delays in seeking care, unmet psychosocial needs, and limited access to precision diagnostics.
A new study suggests that collecting and testing cancer cells in patients' blood could help doctors choose the right breast cancer treatment. The 'labyrinth chip' technology separates cancer cells from other blood cells, allowing researchers to identify biomarkers that distinguish aggressive treatments from less invasive ones.
The NCCN Guidelines Navigator now covers treatment for over a dozen cancer types, including hereditary risk assessment, providing seamless navigation and search capabilities. The new format aims to improve treatment decision-making based on the latest evidence and expert-consensus.
Researchers used ATR-FTIR spectroscopy to analyze tissue samples from patients with metaplastic breast carcinoma, ductal carcinoma in situ, and invasive ductal carcinoma. The study found that specific spectral features were significantly elevated in carcinomatous tissues and could effectively differentiate between normal tissue and can...
A new PET tracer, 64Cu-NOTA-EV-F(ab′2), has been developed for same-day imaging of triple-negative breast and urothelial bladder cancers. The tracer exhibits rapid tumor accumulation and high specificity in nectin-4 positive tumors, enabling accurate non-invasive visualization of this protein.
The Blavatnik Regional Awards recognize exceptional postdoctoral researchers in Life Sciences, Physical Sciences & Engineering, and Chemical Sciences. Veena Padmanaban, Valentin Crépel, and Xiao Xie are this year's winners, honored for groundbreaking discoveries in cancer cell biology, condensed matter physics, and chemical biology tools.
A new breast scan system combines photoacoustic and ultrasound imaging to produce clear 3D images of common breast cancer subtypes. The system, called OneTouch-PAT, takes less than a minute to complete and excels at detecting suspicious lesions in women with dense breast tissue.
Boston College researchers create MapID-tRNA-seq, a method to map chemical modifications and expression of human transfer RNA. The study reveals that tRNA expressions are largely dysregulated in cancerous cells compared to benign cells.
Patients with breast cancer detected through routine screening mammography have improved clinical outcomes, including lower odds of advanced stage breast cancer and death. In contrast, symptom-detected cases were more frequent in older women and had higher mortality rates.
A new study identified six distinct breast tissue patterns associated with an increased risk of invasive breast cancer, particularly among Black women. The radiomic phenotypes may help predict the likelihood of false-negative mammograms or interval cancer diagnoses.
The ESMO Breast Cancer 2025 congress will cover topics such as circulating tumour DNA, immunotherapies, and emerging therapies for managing breast cancer. The event will feature key findings on predictive biomarkers, ctDNA, and tumour-infiltrating lymphocytes.
The SNMMI Mars Shot Research Fund has awarded a $100,000 fellowship to Dr. Randy Ye for his research on FAPI PET imaging for detecting invasive lobular carcinoma. The study aims to assess the ability of FAPI PET and FDG PET to detect tumors and evaluate its impact on patient care.
Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.
A new ASTRO clinical guideline recommends partial breast irradiation as a viable alternative to whole breast radiation for patients with early-stage invasive breast cancer or DCIS, based on evidence from large randomized trials. The guideline provides guidance on patient selection and best practices for delivering effective partial bre...
Researchers analyzed BORIS mutations and protein expression in breast cancer tissue samples, finding frequent mutations associated with breast carcinoma progression. The study suggests the BORIS gene as a potential biomarker for breast cancer.
Researchers discuss the importance of biomarkers in breast lump management, enabling patients to make informed decisions between proactive treatment and watchful waiting. The development of biomarkers could provide personalized risk assessments and guide treatment strategies for women with breast lumps.
The Society of Nuclear Medicine and Molecular Imaging has issued new appropriate use criteria (AUC) for lymphoscintigraphy in sentinel node mapping and lymphedema/lipedema. The AUC covers four clinical categories of cancer, including breast cancer, skin cancer, and others, and addresses pediatric considerations.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
A recent study suggests that routine evaluation of HER2 expression in ductal carcinoma in situ (DCIS) is crucial to avoid under or overtreatment. The research found a significant association between HER2 overexpression and a higher risk of recurrence, as well as improved radiotherapy outcomes.
A new gene classifier has been developed to predict the risk of breast pre-cancer progression in women with ductal carcinoma in situ (DCIS). The study identified 812 genes associated with cancer progression and found that most DCIS cancers were at low risk for recurrence or progression.
Researchers at the University of Basel have successfully differentiated triple-negative breast cancer cells into normal-like cells, opening a new avenue for treatment. The breakthrough uses inhibitors of polo-like kinase 1 to induce estrogen receptor expression, leading to reduced cell growth and tumorigenicity.
Researchers analyzed germline variants in breast cancer patients to identify their role in metastasis development. The study found that host genetic makeup contributes to metastasis through dysregulation of gene expression, promoting the dispersion of metastatic seeds and establishing a conducive environment for their growth.
Researchers at Johns Hopkins Kimmel Cancer Center developed a targeted immunotoxin that delivers into breast ducts, eliminating visible and invisible precancerous lesions in laboratory studies. The treatment showed strong cancer-killing effects in all cell lines and was well-tolerated in mouse models.
A population-based study found that patients with estrogen receptor-positive breast cancer who experienced hot flashes while on adjuvant hormone therapy had worse outcomes and a higher risk of early treatment discontinuation. The study suggests that managing side effects may not be enough to prevent treatment discontinuation, highlight...
Researchers at Mount Sinai have discovered a previously unknown mechanism by which not-yet-malignant breast cancer cells can travel to other organs and 'turn on' to become metastatic. The study identified potential diagnostic biomarkers, including the transcription factor NR2F1, that could help predict relapse.
Researchers have discovered 23 proteins in breast milk that could indicate breast cancer, paving the way for a potential blood test. The study's findings, if confirmed, may enable earlier diagnosis and improve survival rates.
A new study suggests that cardamonin, a compound from the cardamom spice, can kill triple-negative breast cancer cells and reduce PD-L1 expression. The findings hold promise for improving cancer therapy without severe side effects.
A study analyzing blood samples from premenopausal women with breast cancer found high levels of inflammatory markers and low antioxidant levels. These findings may reveal a new diagnostic tool for the disease, with implications for identifying early stages and improving treatment outcomes.
The American Roentgen Ray Society recognizes Drs. Nguyen, Beheshtian, Harfouch, and Hashiba for their outstanding research and education contributions to the field of radiology. The awards honor the candidates' scientific merit and potential impact on imaging and allied sciences research.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
Researchers identified DSS1 as a critical protein in breast cancer progression and found that depleting it makes cancer cells more responsive to lower doses of anti-cancer drugs. This technique may reduce drug-induced side effects in breast cancer patients, providing a safer treatment option.
Researchers found that TMEM165 expression levels alter N-linked glycosylation, promoting the invasion and growth of breast cancer cells. This study suggests a novel role for TMEM165 as a driver of tumor invasion and identifies it as a potential biomarker for breast carcinoma.
A study found that pathologists' diagnoses for breast biopsies have a high rate of disagreement, especially for cases of atypical hyperplasia and ductal carcinoma in situ. The researchers suggest that obtaining a second opinion for these cases could help reduce unnecessary treatment.
A study found that over 10 years, 30.8% of women had diagnostic mammograms, while 61.5% underwent ipsilateral invasive procedures following BCS. The high rates may be due to concerns about recurrence, and the authors highlight the need for better prognostic biomarkers to minimize overtreatment.
A study found that lobular breast cancer (ILC) and ductal breast cancer (IDC) have similar success rates for breast-conserving therapy. ILC patients had larger tumors, but the success rate did not differ between groups.
Women with hereditary non-BRCA breast cancer face a significantly higher risk of developing second primary breast cancers (CBCs), with probabilities ranging from 1.9% to 27.3% over 20 years. Adjuvant hormonal therapy can lower this risk, whereas chemotherapy has no apparent effect.
A study of 1,036 women with ductal carcinoma in situ (DCIS) diagnosed at age 40 or older found that those with high-nuclear-grade lesions had a higher risk of invasive cancer recurrence. Women treated by lumpectomy alone who experienced initial palpation-detected lesions also faced a greater risk of recurrence.
Researchers identified a novel gene, mammaglobin (MG), expressed only in breast cancer tissue. MG was found to be present in 81% of breast cancers and has potential applications for early detection and identification of metastases.